Astrana Health ASTH
$28.90 +$0.22 (+0.77%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $28.90 0.00%
Open$28.52
Prev close$28.68
Day range$28.33 – $29.75
Volume441.0K
Market cap$1.44B
P/E (TTM)26.8
Dividend yield–
ASTH Stock News
Headlines matching Astrana Health or the ASTH ticker, most recent first.
- Truist Financial Maintains Astrana Health(ASTH.US) With Buy Rating
- Oppenheimer Initiates Astrana Health(ASTH.US) With Buy Rating, Announces Target Price $53
- A Quick Look at Today's Ratings for Astrana Health(ASTH.US), With a Forecast Between $41 to $53
- Barclays Maintains Astrana Health(ASTH.US) With Buy Rating, Maintains Target Price $53
- Truist Financial Maintains Astrana Health(ASTH.US) With Buy Rating, Maintains Target Price $55
- Truist Financial Maintains Astrana Health(ASTH.US) With Buy Rating, Announces Target Price $55
- BTIG Maintains Astrana Health(ASTH.US) With Buy Rating, Maintains Target Price $65
- TD Cowen Maintains Astrana Health(ASTH.US) With Buy Rating, Maintains Target Price $50
- Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), Alto Neuroscience, Inc. (ANRO) and Astrana Health (ASTH)
- BTIG Maintains Astrana Health(ASTH.US) With Buy Rating, Raises Target Price to $65 Positive
- TD Cowen Maintains Astrana Health(ASTH.US) With Buy Rating, Raises Target Price to $50 Positive
- Analysts Are Bullish on These Healthcare Stocks: Astrana Health (ASTH), ArriVent BioPharma, Inc. (AVBP) Positive
- Jefferies Maintains Astrana Health(ASTH.US) With Buy Rating, Raises Target Price to $53 Positive
- BTIG Maintains Astrana Health(ASTH.US) With Buy Rating, Raises Target Price to $50 Positive
- Barclays Upgrades Astrana Health(ASTH.US) to Buy Rating, Raises Target Price to $50 Positive
No comments yet — be the first to weigh in on ASTH.
Sign in to join the discussion.